Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Arjun Vasant Balar, Matthew I. Milowsky, Peter H. O'Donnell, Ajjai Shivaram Alva, Marisa Kollmeier, Tracy L Rose, Sean Pitroda, Samuel D. Kaffenberger, Jonathan E. Rosenberg, Kaitlyn Francese, Tsivia Hochman, Judith D Goldberg, Sarah Griglun, Dayna Leis, Gary D. Steinberg, James Wysock, Peter B. Schiff, Nicholas J. Sanfilippo, Samir Taneja, William C. Huang
Institutions: NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of North Carolina at Chapel Hill, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, U-M Rogel Cancer Center, Memorial Sloan Kettering Cancer Center, UNC Lineberger Comprehensive Cancer Center, University of Michigan, New York University, University of Chicago Medical Center, NYU Langone Health, Weill Cornell Medicine
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3172811456